Close Menu

NEW YORK — BioMérieux said on Thursday that it has received CE marking for its two SARS-CoV-2 serology tests.

According to the company, the tests are designed to detect immunoglobulin M and immunoglobulin G antibodies, respectively, against SARS-CoV-2 and have demonstrated over 99 percent specificity. They run on the BioMérieux's Vidas immunoanalyzers and provide results in less than 30 minutes.

Marcy l'Étoile, France-based BioMérieux said it plans to submit the tests to the US Food and Drug Administration for Emergency Use Authorization.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.